ArticleJournal of diabetes research2026
Atherogenic Index of Plasma is Independently Associated With Microalbuminuria in Type 2 Diabetes: A Retrospective Cross-Sectional Study.
Article in Journal of diabetes research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe atherogenic index of plasma (AIP) reflects the balance between proatherogenic and antiatherogenic lipoproteins and is a novel marker of atherosclerosis.
objectivesThis study is aimed at investigating the association between AIP and microalbuminuria in T2DM.
methodsThis retrospective cross-sectional study included 254 patients with Type 2 diabetes mellitus divided into normoalbuminuria group and microalbuminuria group. Models were constructed for regression analysis. Restricted cubic spline was used to analyze the dose-response relationship between AIP and UACR. ROC curve was used to evaluate the discrimination power. The integrated discrimination improvement (IDI) was used to evaluate the incremental value of adding AIP to the base model.
resultsAIP levels were significantly higher in the microalbuminuria group than in the normal albuminuria group (0.32 ± 0.41 vs. 0.19 ± 0.33, p = 0.005). After adjusting for sex, age, blood pressure, BMI, HbA1c, and eGFR, elevated AIP remained independently associated with microalbuminuria (OR = 3.291, 95% CI: 1.411-7.676, p = 0.006). A significant dose-response trend was observed across AIP quartiles (P for trend = 0.010), with the highest quartile showing a 3.34-fold increased risk compared with the lowest (OR = 3.344, 95% CI: 1.397-8.006, p = 0.007). HbA1c (OR = 1.330) and eGFR (OR = 0.970) were also independent risk factors. The discriminative performance of AIP alone was modest, and its incremental value over conventional risk factors was limited.
conclusionAIP is independently associated with microalbuminuria in T2DM with a significant dose-response relationship, suggesting its potential as an adjunctive risk marker for early DKD in primary care. However, its modest discriminative ability precludes use as a standalone screening tool. These hypothesis-generating findings require prospective validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.